Combigan (brimonidine tartrate/timolol maleate) / AbbVie - LARVOL DELTA

Changes in ocular higher-order aberrations and corneal backward light scattering after instillation of brimonidine/brinzolamide versus brimonidine/timolol: a randomized, double-masked, crossover clinical trial (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Glaucoma • Ophthalmology

Triple-fixed Combination of Dorzolamide/Timolol/Brimonidine: Efficacy Study in Bolivian Population. (PubMed, J Curr Glaucoma Pract) - "Triple-fixed Combination of Dorzolamide/Timolol/Brimonidine: Efficacy Study in Bolivian Population. J Curr Glaucoma Pract 2024;18(4):137-141."

Journal • Glaucoma • Ophthalmology

Comparison of Efficacy and Ocular Surface Assessment Between Preserved and Preservative-Free Brimonidine/Timolol Fixed-Combination Eye Drops in Glaucoma Patients: A Parallel-Grouped, Randomized Trial. (PubMed, J Clin Med) - " Preservative-free brimonidine/timolol showed comparable efficacy and safety, better corneal and conjunctival staining score with convenience of installation, and lower stinging and burning sensation. It is expected to be a proper treatment option for patients with glaucoma or ocular hypertension."

Clinical • Journal • Cardiovascular • Glaucoma • Ophthalmology

Randomized Clinical Trial of Intraocular Pressure-Lowering Medications on Preventing Spikes in Intraocular Pressure Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections. (PubMed, Ophthalmol Ther) - "Topical fixed combination anti-glaucoma medication used as a prophylactic treatment before intravitreal anti-VEGF injections significantly prevented IOP spikes post-injection, with a comparable effect among three medications. Prophylactic treatment of IOP spikes should be considered as standard care to prevent further damage in patients with compromised retinal vascular and optic nerve perfusion."

Clinical • Journal • Allergy • Glaucoma • Immunology • Ophthalmology • Retinal Disorders

Peace After The Storm: Implantable Collamer Lens Repositioning And Gonio Wash Halt Pigment Release Post Implantation (ESCRS 2024) - "He was then started on topical antiglaucoma G.Combigan to stop further IOP spike...Conclusion/Take home message: Pigment dispersion syndrome can lead to irreversible damage of trabecular meshwork if the pigments are not removed in time. This is a case report of a patient who had early intervention to control pigments release by vertically rotating the ICL and also gonio wash."

Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis

Severe intraocular pressure rise after implantable collamer lens implantation. (PubMed, J Cataract Refract Surg) - "Prednisolone acetate 0.1% ophthalmic suspension eye drops and ofloxacin 0.3% ophthalmic solution eye drops 4 times daily were prescribed prophylactically 2 days preoperatively...The patient was instructed to reduce prednisolone to 2 times a day, discontinue brimonidine, and start brimonidine/timolol (Combigan) 2 times a day and latanoprost at bedtime in both eyes...The patient was instructed to reduce prednisolone to once a day, continue brimonidine/timolol 2 times a day and latanoprost at bedtime, and start acetazolamide (Diamox) 250 mg 2 times a day...What is the most likely mechanism underlying this patient's elevated IOP? What additional diagnostic workup would aid you in making the correct diagnosis?"

Journal • Glaucoma • Ophthalmology • Pain

Topical application of hypotensive drugs for the prevention of intraocular pressure elevation after intravitreal injections of anti-VEGF drugs (PubMed, Vestn Oftalmol) - "Study patients that received instillations of brimonidine-timolol combination of one drop into the conjunctival sac 1 day before the injection and on the day of the injection showed the maximum decrease in IOP compared to patients of the other groups."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Understanding the treatment paradigm and the sequencing of antiglaucoma fixed-dose combinations in a tertiary center in South India. (PubMed, Indian J Ophthalmol) - "This study is a fairly large study with a minimum of a 5-year follow-up of patients with POAG and OHT and gives insights into the treatment patterns, use of FDCs, and the need for multiple medications over time."

Journal • Cardiovascular • Glaucoma • Ophthalmology

An AI Model for Identifying High-Risk Patients for Blindness due to Glaucoma (ARVO 2024) - "Additionally, Medical conditions such as high blood pressure, Alzheimer's disease, cardiac diseases, Parkinson's disease, and use of specific glaucoma medications including Brimonidine, Timolol, Combigan, Cosopt and Dorzolamide were significantly associated with an increased risk of blindness in glaucoma patients. The developed AI model demonstrated promising capabilities in identifying high-risk patients prone to glaucoma-induced blindness. In this study, significant risk factors were identified, contributing valuable insights to the understanding and management of blindness in patients with glaucoma."

Clinical • Glaucoma • Ophthalmology

Glaucoma Drug Prescription Pattern in North India: Public vs Private Sector Hospitals. (PubMed, J Curr Glaucoma Pract) - "Brimonidine and brinzolamide (14.17%) was the most prescribed combination in group II, while Brimonidine with Timolol (7.87%) in group I. In group I, Timolol and Travoprost were the most prescribed medications for both PACD and POAG...Bhartiya S, Ichhpujani P, Parmar UPS, et al.Glaucoma Drug Prescription Pattern in North India: Public vs Private Sector Hospitals. J Curr Glaucoma Pract 2024;18(1):16-22."

Journal • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension (clinicaltrials.gov) - P3 | N=406 | Completed | Sponsor: EMS | Recruiting ➔ Completed

Trial completion • Cardiovascular • Glaucoma • Ophthalmology

The First Study on Fixed-Dose Combination of Timolol + Brimonidine + Brinzolamide Eye Drops for OAG/Ocular Hypertension (AAO 2023) - "Conclusion Our study establishes that triple FDC is safe, effective and well tolerated. Triple FDC can be an effective option in glaucoma management."

Glaucoma • Ophthalmology

BCT: Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hypertensive (clinicaltrials.gov) - P4 | N=60 | Completed | Sponsor: CHA University

New P4 trial • Glaucoma • Ophthalmology

Patient Factors Influencing Intraocular Penetration of Brimonidine-Related Eye Drops in Adults: A Post Hoc Pooled Analysis. (PubMed, Ophthalmol Ther) - "The findings of this study emphasize the necessity of considering individual differences in ocular pharmacokinetics during drug therapy (formulation design of the eye drops and dose regimen)."

Journal • Retrospective data • Ophthalmology

Assessment of corneal sublayer thickness changes in glaucoma patients using optical coherence tomography and correlation of epithelial layer thinning with dry eye monitoring: Assessment of corneal thickness changes in glaucoma patients. (PubMed, Photodiagnosis Photodyn Ther) - "CET and CCT thinning were higher in the Tomec and Combigan groups than in the Alphagan group. Furthermore, although CCT reduction was significant in the Tomec and Combigan groups, its effect on IOP underestimation was approximately 1%. Furthermore, the positive correlation between CET and TBUT suggests that CET measurement with AS-OCT may also be useful in dry eye monitoring."

Journal • Dry Eye Disease • Glaucoma • Ophthalmology

Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study. (PubMed, Adv Ther) - "As BTFC offered better tolerability than DTFC with comparable reduction in IOP, we recommend it as an alternative for patients who experience ocular discomfort with DTFC-prostaglandin analogue combination therapy."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Managing primary open-angle glaucoma in the setting of suboptimal surgical outcomes in the fellow eye. (PubMed, J Cataract Refract Surg) - "The addition of acetazolamide lowered the pressure to 19 mm Hg in both eyes, but she tolerated it poorly...However, by postoperative week 3, IOP returned to 27 mm Hg, and despite restarting latanoprost-netarsudil and finishing her steroid taper, IOP remained at 27 mm Hg by postoperative week 6...Knowing her postoperative course in the left eye, how would you manage the right eye? In addition to currently available options, would you consider a supraciliary shunt such as the MINIject (iSTAR) if such a device were U.S. Food and Drug Administration (FDA)-approved?"

Journal • Cataract • Glaucoma • Ophthalmology

Prophylaxis for Anti-VEGF-induced IOP Elevation (clinicaltrials.gov) - P=N/A | N=0 | Withdrawn | Sponsor: McMaster University | N=107 ➔ 0 | Unknown status ➔ Withdrawn

Enrollment change • Trial withdrawal • Cardiovascular • Glaucoma • Wet Age-related Macular Degeneration

UPSHER-SMITH EXPANDS OPHTHALMIC PORTFOLIO WITH LAUNCH OF BRIMONIDINE TARTRATE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION (PRNewswire) - "Upsher-Smith Laboratories....today announced it has expanded its ophthalmic portfolio with the launch of Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5%, an AB-rated generic equivalent to the branded product Combigan....The brimonidine tartrate and timolol maleate ophthalmic solution market had U.S. sales of approximately $392 million for the 12 months ending February 2023 according to IQVIA."

Generic launch • Glaucoma

Crossover randomized multicentre clinical trial comparing the efficacy and tolerability of fixed-combinations of 0.1% brimonidine/0.5% timolol versus 1% dorzolamide/0.5% timolol as adjunctive therapies to prostaglandin analogues: Aibeta Crossover Study (ARVO 2023) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Glaucoma • Ophthalmology

Effect of patient factors on ocular pharmacokinetics in ophthalmic drug administration (ARVO 2023) - "The subjects were 42 patients who were scheduled for vitrectomy and received brimonidine related eye drops (0.1% brimonidine tartrate ophthalmic solution, 0.1% brimonidine tartrate and 0.68% timolol maleate fixed-combination ophthalmic solution or 0.1% brimonidine tartrate and 1% brinzolamide fixed-combination suspension) twice daily for 1 week...Describe the big picture and the implications of your findings, not the study itself and the associated details. We evaluated effect of patient factors on ocular pharmacokinetics in order to achieve the formulation design of eye drops and the drug therapy in consideration of individual differences."

Clinical • PK/PD data • Ophthalmology

Cationic liposomes as promising vehicles for timolol/brimonidine combination ocular delivery in glaucoma: formulation development and in vitro/in vivo evaluation. (PubMed, Drug Deliv Transl Res) - "The results also showed that liposomal formulation has a therapeutic effect in reducing intraocular pressure. It seems that the selected liposomal formulation made by thin layer hydration can act as a suitable drug carrier to increase the effectiveness of the fixed combination of timolol maleate and brimonidine tartrate and be proposed as a new drug formulation for targeted and controlled drug delivery in the treatment of glaucoma."

Journal • Preclinical • Glaucoma • Ophthalmology

Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: An interventional study. (PubMed, PLoS One) - "The majority of patients who received a 0.1% brimonidine tartrate and 0.5% timolol topical fixed-combination ophthalmic solution showed a brimonidine concentration >2 nM in the vitreous humor. Brimonidine and timolol may be distributed in the ocular tissues through an identical pathway after topical instillation."

Journal • Ophthalmology • Retinal Disorders

Underreporting and Triggering Factors for Reporting ADRs of Two Ophthalmic Drugs: A Comparison between Spontaneous Reports and Active Pharmacovigilance Databases. (PubMed, Healthcare (Basel)) - "(1) Aims of the study: calculating the underreporting ratio for two different medications, a fixed combination of 0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide (antiglaucoma) and a fixed combination of sodium hyaluronate 0.1% + chondroitin sulfate 0.18% (artificial tears) for characterizing the features influencing the reporting of adverse drug reactions (ADRs) in spontaneous reporting...(4) The underreporting ratio of ADRs related to ophthalmic medications indicates worry since the cornerstone of pharmacovigilance focuses on spontaneous reporting. Additionally, since underreporting seems to b selective, the role of certain aspects, such as gender, seriousness, severity, and unexpected ADRs, must be considered in future research."

Adverse events • Journal • Glaucoma • Ophthalmology

A Deep Learning–Based Smartphone Application Increases Patient's Medication Identification Speed and Accuracy: A Clinical Case Series (AAO 2022) - "Here, we expanded the model's database and tested its effectiveness with patients from an academic glaucoma clinic. An iOS app-embedded CNN (MobileNetV3) was trained with 9860 images and tested on 1088 images of 8 medications: Pred Forte, Vigamox, Rocklatan, Rhopressa, Xalatan, Trusopt, Combigan, and Alphagan. Utilization of an iOS application integrated with MobileNetV3 architecture is a promising tool to help visually-impaired patients quickly and accurately identify their ophthalmic medication bottles."

Clinical • Glaucoma • Ophthalmology